Data Sheet (Cat.No.T21470)

TargetMol

Davunetide

Chemical Properties



CAS No. : 211439-12-2

Formula: C36H60N10O12

Molecular Weight: 824.92

Storage: Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Davunetide, an eight-amino-acid peptide (NAPVSIPQ), demonstrates potent neuroprotection in vitro and in vivo, enhances functional daily behaviors in schizophrenia patients, and increases memory scores in individuals with amnestic mild cognitive impairment.
Targets(IC50)	Beta Amyloid,Microtubule Associated

Solubility Information

Solubility	DMSO: Soluble, H2O: Insoluble, (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.2122 mL	6.0612 mL	12.1224 mL
5 mM	0.2424 mL	1.2122 mL	2.4245 mL
10 mM	0.1212 mL	0.6061 mL	1.2122 mL
50 mM	0.0242 mL	0.1212 mL	0.2424 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Arya A, Meena R, Sethy NK, Das M, Sharma M, Bhargava K. NAP (davunetide) protects primary hippocampus culture by modulating expression profile of antioxidant genes during limiting oxygen conditions. Free Radic Res. 2015 Apr;49(4):440-52. doi: 10.3109/10715762.2015.1011153. Epub 2015 Mar 2. PubMed PMID: 25727410.

Magen I, Ostritsky R, Richter F, Zhu C, Fleming SM, Lemesre V, Stewart AJ, Morimoto BH, Gozes I, Chesselet MF. Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein. Pharmacol Res Perspect. 2014 Oct;2(5):e00065. doi: 10.1002/prp2.65. Epub 2014 Aug 6. PubMed PMID: 25505609; PubMed Central PMCID: PMC4186425.

Sethy NK, Sharma NK, Das M, Bhargava K. Protein profiling reveals antioxidant and signaling activities of NAP (Davunetide) in rodent hippocampus exposed to hypobaric hypoxia. J Mol Neurosci. 2014 Nov;54(3):414-29. doi: 10.1007/s12031-014-0381-9. Epub 2014 Jul 20. PubMed PMID: 25038875.

Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul;13(7):676-85. doi: 10.1016/S1474-4422(14)70088-2. Epub 2014 May 27. PubMed PMID: 24873720; PubMed Central PMCID: PMC4129545.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481